]>

Table 4: Univariate analysis of factors regarding tumor progression and death using TMA-3.

Variable   Categorization Death Tumor progression $n$ events $P^{*}$ $n$ events $P^{*}$ Advance melanoma patients  Age         $<$60 years 12 7 0.152 12 11 0.163         $\ge$60 years 22 14 22 18  Initial tumor stage        pT1 2 1 0.690 2 2 0.016        pT2 1 1 1 1        pT3 13 9 13 11        pT4 9 6 9 6        Melanoma in situ 1 0 1 1  Initial regional lymph node status        pN0 11 6 0.980 11 9 0.894        pN1 9 8 9 8        pN2 6 4 6 5        pN3 2 1 2 1  Study therapy        A: trofosfamide 12 10 0.570 12 10 0.898        B: trofosfamide + rofecoxib + pioglitazone 23 12 23 20  CRP        normal or $<30\%$ decrease or increase 14 9 0.115 14 11 0.128         $>30\%$ decrease 10 10 10 10  Cytoplasmic COX2 IHC        score 0 to 1+ 14 10 0.505 14 13 0.338        score 2+ to 3+ 21 12 21 17  Nuclear PPARG IHC        score 0 22 15 0.179 22 21 0.044        score 1+ to 3+ 13 7 13 9

${}^{*}\text{L}$og-rank test (two-sided).